HomeMarkets Markets In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients By news November 12, 2023 0 257 FacebookTwitterPinterestWhatsApp Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed …This post was originally published on this site Share FacebookTwitterPinterestWhatsApp Subscribe Login Notify of new follow-up comments new replies to my comments Please login to comment 0 Comments Inline Feedbacks View all comments Stay Connected156,730FansLike396,312FollowersFollow2,310SubscribersSubscribe Latest Articles Hot Items China Will Soon Lose the Title of “World’s Manufacturer” Markets DOJ: Russia Aimed Propaganda at Gamers, Minorities to Swing 2024 Election Markets OpenAI is looking for new ways to pay its bills Markets More than 90 company executives, 100 law enforcement officials back Harris Markets CTEM: The next frontier in cybersecurity Load more